Abstract
Graphical Abstract
HIV/AIDS Drugs
In article 2203198, Garry Laverty and co-workers develop a long-acting injectable drug delivery implant composed of a short peptide sequence attached to the HIV/AIDS drug zidovudine. Upon injection, this aqueous solution-based formulation rapidly forms a drug-releasing hydrogel implant in response to phosphatase enzymes present within the skin space. Clinically relevant concentrations of zidovudine were delivered to rat models for 35 days, outlining the promise of this platform to improve patient adherence to HIV/AIDS drugs.
HIV/AIDS Drugs
In article 2203198, Garry Laverty and co-workers develop a long-acting injectable drug delivery implant composed of a short peptide sequence attached to the HIV/AIDS drug zidovudine. Upon injection, this aqueous solution-based formulation rapidly forms a drug-releasing hydrogel implant in response to phosphatase enzymes present within the skin space. Clinically relevant concentrations of zidovudine were delivered to rat models for 35 days, outlining the promise of this platform to improve patient adherence to HIV/AIDS drugs.
| Original language | English |
|---|---|
| Article number | 2370100 |
| Journal | Advanced Healthcare Materials |
| Volume | 12 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - 17 Jul 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Enzyme‐triggered l ‐ α / d ‐peptide hydrogels as a long‐acting injectable platform for systemic delivery of HIV/AIDS drugs(Adv. Healthcare Mater. 18/2023) Frontispiece'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver